title: [Omeprazole, amoxicillin and clarithromycin in the treatment of helicobacterpylori, in 7 and 10-day regimens].
abstract: OBJECTIVE
  The most accepted treatment for infection by Helicobacter pylori is the proton pump inhibitor based therapy with two antibiotics. However, there is no consensus regarding the duration. The purpose here was to compare eradication percentages in the omeprazole+amoxicillin+clarithromycin regimen administered during 7 days versus 10 days and confront the results with a previous 14-day* experience in Peru.
  
  
  METHODS
  Patients from the Central Military Hospital and Peruvian-Japanese Hospital evidencing chronic upper gastrointestinal tract symptoms were recruited. We excluded patients with peptic ulcer. Biopsies were taken for diagnosis, for urease and PCR tests, culture and coloring with silver. Omeprazole+clarithromycin+amoxicillin was used during 7 days versus 10 days. Control endoscopy was performed one month after treatment had been completed and molecular biology techniques were used to differentiate recurrences from new infections. Susceptibility to clarithromycin was assessed.
  
  
  RESULTS
  36 patients were included in each group. Eradication was the same in both groups: 86.1% (31/36). In several patients in whom the bacteria persisted, the same initial nucleus was found. In a previous study* using this same regimen during 14 days, a 93% eradication was obtained. 91.18% of our samples were susceptible to clarithromycin.
  
  
  CONCLUSIONS
  In Peru, the omeprazole+clarithromycin+amoxicillin combination gives results higher than 80% in the eradication of infection by Helicobacter pylori. The 7 and 10 days regimens eradicated the bacteria in 86% of our patients.
authors.affiliation: Hospital Militar Central-Dpto de Gastroenterología.
authors.forename: Wilson
authors.initials: W
authors.lastname: Rodríguez
authors.forename: Arturo
authors.initials: A
authors.lastname: Pareja Cruz
authors.forename: Luis
authors.initials: L
authors.lastname: Yushimito
authors.forename: Alberto
authors.initials: A
authors.lastname: Ramírez Ramos
authors.forename: Robert H
authors.initials: RH
authors.lastname: Gilman
authors.forename: José
authors.initials: J
authors.lastname: Watanabe Yamamoto
authors.forename: Carlos
authors.initials: C
authors.lastname: Rodríguez Ulloa
authors.forename: Daniel
authors.initials: D
authors.lastname: Mendoza Requena
authors.forename: José
authors.initials: J
authors.lastname: Guerra Valencia
authors.forename: Julio
authors.initials: J
authors.lastname: Leey Casella
authors.forename: Erick
authors.initials: E
authors.lastname: Chinga Alayo
authors.forename: Billie
authors.initials: B
authors.lastname: Velapatiño
authors.forename: Teresa
authors.initials: T
authors.lastname: Valencia
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole